Proton Pump Inhibitors Market

Proton-pump inhibitors (PPIs) are a group of medications whose main action is a pronounced and long-lasting reduction of stomach acid production.

Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.

PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.

Medically used proton pump inhibitors: Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole.

Proton Pump Inhibitors Market contains market size and forecasts of Proton Pump Inhibitors in global, including the following market information:

Global Proton Pump Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Proton Pump Inhibitors Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Proton Pump Inhibitors companies in 2021 (%)

The global Proton Pump Inhibitors market was valued at 12540 million in 2021 and is projected to reach US$ 10090 million by 2028, at a CAGR of -3.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Dexlansoprazole Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Proton Pump Inhibitors include Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan and AOSAIKANG Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Proton Pump Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Proton Pump Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Proton Pump Inhibitors Market Segment Percentages, by Type, 2021 (%)

• Dexlansoprazole
• Esomeprazole
• Lansoprazole
• Omeprazole
• Pantoprazole
• Rabeprazole

Global Proton Pump Inhibitors Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Proton Pump Inhibitors Market Segment Percentages, by Distribution Channel, 2021 (%)

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Proton Pump Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Proton Pump Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Proton Pump Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Proton Pump Inhibitors revenues share in global market, 2021 (%)
• Key companies Proton Pump Inhibitors sales in global market, 2017-2022 (Estimated), (M Units)
• Key companies Proton Pump Inhibitors sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Takeda
• Pfizer
• AstraZeneca
• Bayer
• Sun Pharma
• Teva
• Eisai Co.
• Mylan
• AOSAIKANG Pharma
• Luoxin Pharma
• LIVZON
• Eastchina Pharma